Literature DB >> 1923535

Aberrant expression of the p53 oncoprotein is a common feature of a wide spectrum of human malignancies.

J Bártek1, J Bártková, B Vojtĕsek, Z Stasková, J Lukás, A Rejthar, J Kovarík, C A Midgley, J V Gannon, D P Lane.   

Abstract

Accumulation of the p53 protein was analysed in 212 human malignant lesions. Immunohistochemical staining with new polyclonal (CM-1) and monoclonal antibodies (BP 53-12 and BP53-24) to p53 on methacarn-fixed paraffin sections showed positive staining in 161 (76%). The positive tumours were found across a wide range of human malignancies including breast, colon, stomach, bladder and testis carcinomas, soft-tissue sarcomas and melanomas. The staining was always confined to the malignant lesion. Immunoprecipitation and quantitative ELISA assays established that the positive staining was associated with accumulation of the protein and that the protein was frequently in a mutant conformation. Accumulation of mutant p53 protein is therefore a common feature of human malignant disease.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1923535

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  107 in total

1.  Significance of Wet Autoclave Pretreatment in Immunohistochemistry.

Authors:  József Piffkó; Dietmar Öfner; Rita Dreier; Werner Böcker; Kurt Werner
Journal:  Pathol Oncol Res       Date:  1996       Impact factor: 3.201

2.  Immunostaining of p53 protein in ovarian carcinoma: correlation with histopathological data and clinical outcome.

Authors:  A Reles; A Schmider; M F Press; I Schönborn; W Friedmann; S Huber-Schumacher; T Strohmeyer; W Lichtenegger
Journal:  J Cancer Res Clin Oncol       Date:  1996       Impact factor: 4.553

3.  Simultaneous evaluation of maspin and CXCR4 in patients with breast cancer.

Authors:  Efthimia Tsoli; Petros K Tsantoulis; Alexandros Papalambros; Branko Perunovic; David England; David A Rawlands; Gary M Reynolds; Dimitrios Vlachodimitropoulos; Susan L Morgan; Chara A Spiliopoulou; Thanos Athanasiou; Vassilis G Gorgoulis
Journal:  J Clin Pathol       Date:  2006-06-02       Impact factor: 3.411

4.  Prognostic value of immunohistochemistry for p53 in primary soft-tissue sarcomas: a multivariate analysis of five antibodies.

Authors:  P Würl; H Taubert; A Meye; D Berger; C Lautenschläger; H J Holzhausen; H Schmidt; H Kalthoff; F W Rath; H Dralle
Journal:  J Cancer Res Clin Oncol       Date:  1997       Impact factor: 4.553

5.  p53 gene alterations and protein accumulation in colorectal cancer.

Authors:  R Bertorelle; G Esposito; C Belluco; L Bonaldi; A Del Mistro; D Nitti; M Lise; L Chieco-Bianchi
Journal:  Clin Mol Pathol       Date:  1996-04

6.  Cytotoxic susceptibility and defective MHC class I expression do not correlate with mutation of p53 in human carcinomas.

Authors:  Z Végh; P Wang; F Vánky; C Hising; K Sjöwall; B Larsson; E Klein
Journal:  Cancer Immunol Immunother       Date:  1994-01       Impact factor: 6.968

7.  Aberrant p53 expression in astrocytic neoplasms of the brain: association with proliferation.

Authors:  H Haapasalo; J Isola; P Sallinen; H Kalimo; H Helin; I Rantala
Journal:  Am J Pathol       Date:  1993-05       Impact factor: 4.307

8.  Ras activation of genes: Mob-1 as a model.

Authors:  P Liang; L Averboukh; W Zhu; A B Pardee
Journal:  Proc Natl Acad Sci U S A       Date:  1994-12-20       Impact factor: 11.205

9.  Thymoma: tumour type related to expression of epidermal growth factor (EGF), EGF-receptor, p53, v-erb B and ras p21.

Authors:  Y Hayashi; N Ishii; C Obayashi; K Jinnai; K Hanioka; Y Imai; H Itoh
Journal:  Virchows Arch       Date:  1995       Impact factor: 4.064

10.  Overexpression of p53 protein in Barrett's syndrome with malignant transformation.

Authors:  J F Fléjou; F Potet; F Muzeau; F Le Pelletier; F Fékété; D Hénin
Journal:  J Clin Pathol       Date:  1993-04       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.